Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tryptamine Therapeutics Limited (AU:TYP)
:TYP
TYP Stock Chart & Stats
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume1.74M
Average Volume (3M)0.00
Market Cap
AU$48.50M
Enterprise ValueAU$18.55M
Total Cash (Recent Filing)4.42M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.71
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,276,421,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Standard Deviation0.15
R-Squared0.29
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Tryptamine Therapeutics News
PremiumCompany Announcements
Tryptamine Therapeutics Updates Security Issuance Proposal
PremiumCompany Announcements
Tryptamine Therapeutics Updates Proposed Securities Issue
PremiumCompany Announcements
Tryptamine Therapeutics Appoints New Auditor Amid Global Expansion
PremiumCompany Announcements
Tryptamine Therapeutics Announces Change in Director’s SecuritiesPremiumCompany Announcements
Tryptamine Therapeutics Announces Lapse of Director OptionsPremiumCompany Announcements
Tryptamine Therapeutics Announces Change in Director’s Interest---
Options Prices
Currently, No data available
---
Ownership Overview
TYP FAQ
What was Tryptamine Therapeutics Limited’s price range in the past 12 months?
Tryptamine Therapeutics Limited lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is Tryptamine Therapeutics Limited’s market cap?
Tryptamine Therapeutics Limited’s market cap is AU$48.50M.
When is Tryptamine Therapeutics Limited’s upcoming earnings report date?
Tryptamine Therapeutics Limited’s upcoming earnings report date is Feb 20, 2025 which is 2 days ago.
How were Tryptamine Therapeutics Limited’s earnings last quarter?
Tryptamine Therapeutics Limited released its earnings results on Sep 06, 2024. The company reported -AU$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.004.
Is Tryptamine Therapeutics Limited overvalued?
According to Wall Street analysts Tryptamine Therapeutics Limited’s price is currently Overvalued.
Does Tryptamine Therapeutics Limited pay dividends?
Tryptamine Therapeutics Limited does not currently pay dividends.
What is Tryptamine Therapeutics Limited’s EPS estimate?
Tryptamine Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tryptamine Therapeutics Limited have?
Tryptamine Therapeutics Limited has 1,276,421,900 shares outstanding.
What happened to Tryptamine Therapeutics Limited’s price movement after its last earnings report?
Tryptamine Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Tryptamine Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:TYP
---
Tryptamine Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:TYP Sentiment 70%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.74%
12-Months-Change
Fundamentals
Return on Equity
-241.85%
Trailing 12-Months
Asset Growth
24.42%
Trailing 12-Months
Company Description
Tryptamine Therapeutics Limited
Exopharm Ltd is a biopharmaceutical company operating in Australia. The company is engaged in developing and commercializing exosomes as therapeutic agents. Its products Plexaris and Exomere are developed using LEAP manufacturing process.
---
Technical Analysis
Elixinol Wellness
―
Cann Group Ltd.
―
Zelira Therapeutics
―
Althea Group Holdings Ltd.
―
Botanix Pharmaceuticals Limited
―
---